PCM
ALGS icon

Prelude Capital Management’s Aligos Therapeutics ALGS Stock Holding History

Prelude Capital Management’s Portfolio ALGS Stock Details ALGS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-1,084
Closed -$58K – 1799
2022
Q1 		$58K Buy
+1,084
New +$86.8K ﹤0.01% 1480

Other funds holding ALGS

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Prelude Capital Management's ALGS Position: Q2 2022 in Review

Prelude Capital Management sold out of Aligos Therapeutics (ALGS) in Q2 2022, closing a stake of 1,084 shares — an estimated $58K sold.

Prelude Capital Management first reported a position in ALGS in Q1 2022 and held it in 1 quarter. The position peaked at $58K in Q1 2022. 59 funds tracked by Wall St. Rank hold ALGS as of Q2 2022.

  • Prelude Capital Management reported no remaining Aligos Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Prelude Capital Management sold 1,084 Aligos Therapeutics shares in Q2 2022, an estimated $58K.
  • Prelude Capital Management first reported a position in Aligos Therapeutics in Q1 2022 and held it in 1 quarter.
  • Prelude Capital Management's Aligos Therapeutics position peaked at $58K in Q1 2022.
  • 59 funds tracked by Wall St. Rank held Aligos Therapeutics as of Q2 2022.

Based on Prelude Capital Management's 13F filing for Q2 2022, filed 15 Aug 2022.